Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.

Park DJ, Kang JH, Lee JW, Lee KE, Wen L, Kim TJ, Park YW, Park SH, Lee SS.

Arthritis Care Res (Hoboken). 2015 Feb;67(2):280-7. doi: 10.1002/acr.22409.

2.

Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.

Plumpton CO, Alfirevic A, Pirmohamed M, Hughes DA.

Rheumatology (Oxford). 2017 Oct 1;56(10):1729-1739. doi: 10.1093/rheumatology/kex253. Review.

PMID:
28957559
3.

Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.

Dong D, Tan-Koi WC, Teng GG, Finkelstein E, Sung C.

Pharmacogenomics. 2015 Nov;16(16):1781-93. doi: 10.2217/pgs.15.125. Epub 2015 Nov 10.

PMID:
26554739
4.

HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.

Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, Park HW, Chang YS, Cho SH, Min KU, Kang HR.

Nephrol Dial Transplant. 2011 Nov;26(11):3567-72. doi: 10.1093/ndt/gfr060. Epub 2011 Mar 10.

PMID:
21393610
5.

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.

Ko TM, Tsai CY, Chen SY, Chen KS, Yu KH, Chu CS, Huang CM, Wang CR, Weng CT, Yu CL, Hsieh SC, Tsai JC, Lai WT, Tsai WC, Yin GD, Ou TT, Cheng KH, Yen JH, Liou TL, Lin TH, Chen DY, Hsiao PJ, Weng MY, Chen YM, Chen CH, Liu MF, Yen HW, Lee JJ, Kuo MC, Wu CC, Hung SY, Luo SF, Yang YH, Chuang HP, Chou YC, Liao HT, Wang CW, Huang CL, Chang CS, Lee MT, Chen P, Wong CS, Chen CH, Wu JY, Chen YT, Shen CY; Taiwan Allopurinol-SCAR Consortium.

BMJ. 2015 Sep 23;351:h4848. doi: 10.1136/bmj.h4848.

6.

Drug eruptions induced by allopurinol associated with HLA-B*5801.

Zeng M, Zhang M, Liu F, Yan W, Kong Q, Sang H.

Indian J Dermatol Venereol Leprol. 2015 Jan-Feb;81(1):43-5. doi: 10.4103/0378-6323.148566. Review.

7.

HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.

Yeo SI.

Int J Rheum Dis. 2013 Jun;16(3):254-7. doi: 10.1111/1756-185X.12050. Epub 2013 Apr 26. Review.

PMID:
23981744
8.

Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.

Mitri G, Wittbrodt ET, Turpin RS, Tidwell BA, Schulman KL.

J Manag Care Spec Pharm. 2016 Apr;22(4):326-36. doi: 10.18553/jmcp.2016.22.4.326.

9.

Analysis of Ocular Manifestation and Genetic Association of Allopurinol-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in South Korea.

Lee HS, Ueta M, Kim MK, Seo KY, Sotozono C, Kinoshita S, Yoon KC.

Cornea. 2016 Feb;35(2):199-204. doi: 10.1097/ICO.0000000000000708.

PMID:
26655481
10.

Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.

Stevenson M, Pandor A.

Health Technol Assess. 2009 Oct;13 Suppl 3:37-42. doi: 10.3310/hta13suppl3/06. Review.

11.
12.

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MT.

Clin Pharmacol Ther. 2013 Feb;93(2):153-8. doi: 10.1038/clpt.2012.209. Epub 2012 Oct 17.

13.

Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong.

Chiu ML, Hu M, Ng MH, Yeung CK, Chan JC, Chang MM, Cheng SH, Li L, Tomlinson B.

Br J Dermatol. 2012 Jul;167(1):44-9. doi: 10.1111/j.1365-2133.2012.10894.x. Epub 2012 May 8.

PMID:
22348415
14.

Safety profile of anti-gout agents: an update.

Stamp LK.

Curr Opin Rheumatol. 2014 Mar;26(2):162-8. doi: 10.1097/BOR.0000000000000031. Review.

PMID:
24378930
15.

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.

Wu R, Cheng YJ, Zhu LL, Yu L, Zhao XK, Jia M, Wen CH, Long XZ, Tang T, He AJ, Zeng YY, Ma ZF, Zheng Z, Ni MZ, Cai GJ.

Oncotarget. 2016 Dec 6;7(49):81870-81879. doi: 10.18632/oncotarget.13250. Review.

16.

Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.

Saokaew S, Tassaneeyakul W, Maenthaisong R, Chaiyakunapruk N.

PLoS One. 2014 Apr 14;9(4):e94294. doi: 10.1371/journal.pone.0094294. eCollection 2014.

17.

Cost-effectiveness of allopurinol and febuxostat for the management of gout.

Jutkowitz E, Choi HK, Pizzi LT, Kuntz KM.

Ann Intern Med. 2014 Nov 4;161(9):617-26. doi: 10.7326/M14-0227.

PMID:
25364883
18.

Cost-effectiveness analysis of febuxostat in patients with gout in Spain.

Perez-Ruiz F, Díaz-Torné C, Carcedo D.

J Med Econ. 2016 Jun;19(6):604-10. doi: 10.3111/13696998.2016.1149482. Epub 2016 Feb 22.

PMID:
26855041
19.

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.

Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W.

Pharmacogenet Genomics. 2009 Sep;19(9):704-9. doi: 10.1097/FPC.0b013e328330a3b8.

PMID:
19696695
20.

Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout.

Meltzer M, Pizzi LT, Jutkowitz E.

Evid Based Med. 2012 Aug;17(4):105-8. doi: 10.1136/ebmed-2011-100065. Epub 2012 Feb 18.

PMID:
22345034

Supplemental Content

Support Center